证券代码：003017 证券简称：大洋生物 公告编号：2025-088 浙江大洋生物科技集团股份有限公司 第六届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江大洋生物科技集团股份有限公司（以下简称"公司"或"本公司"）第 六届董事会第六次会议于 2025 年 9 月 12 日以现场形式召开，会议通知已于 2025 年 9 月 12 日以书面或电子邮件方式发出。本次会议由公司董事长陈阳贵先生主 持，会议应出席的董事 9 人，实际出席的董事 9 人。公司高级管理人员列席。本 次会议的通知、召集和召开符合《公司法》等有关法律、行政法规、部门规章、 规范性文件和《公司章程》的有关规定，合法有效。 二、董事会会议审议情况 本次会议经过投票表决，一致通过如下议案： （一）审议通过《关于公司 2024 年员工持股计划第一个解锁期届满暨解 锁条件成就的议案》 1.议案内容：公司 2024 年员工持股计划第一个锁定期于 2025 年 9 月 10 日届满，根据 2024 年度公司业绩完成情况及持有人个人绩效考核情况，第一 ...

Market Overview - On September 12, the chemical raw materials sector declined by 0.41%, with Dayang Bio leading the drop [1] - The Shanghai Composite Index closed at 3883.69, up 0.22%, while the Shenzhen Component Index closed at 12996.38, up 0.13% [1] Stock Performance - Notable gainers in the chemical raw materials sector included: - Zhenhua Co., Ltd. (603067) with a closing price of 18.59, up 4.97% [1] - ST Yatai (000691) with a closing price of 7.44, up 4.94% [1] - Shilong Industry (002748) with a closing price of 10.17, up 4.31% [1] - Major decliners included: - Dayang Bio (003017) with a closing price of 33.78, down 3.82% [2] - Sanyou Chemical (600409) with a closing price of 5.97, down 2.45% [2] - Kaisheng New Materials (301069) with a closing price of 23.12, down 2.41% [2] Capital Flow - The chemical raw materials sector experienced a net outflow of 209 million yuan from main funds, while retail funds saw a net inflow of 89.33 million yuan [2] - Key stocks with significant capital flow included: - Longbai Group (002601) with a main fund net inflow of 26.73 million yuan [3] - Zhongke Titanium White (002145) with a main fund net inflow of 25.74 million yuan [3] - Huayi Group (600623) with a main fund net inflow of 22.27 million yuan [3]

Company Overview - Zhejiang Dayang Biological Technology Group Co., Ltd. is located in Dayang Town, Jiande City, Hangzhou, Zhejiang Province, and was established on January 1, 1976. The company was listed on October 26, 2020 [1] - The main business involves the production and sales of chemical raw materials, including inorganic salts and veterinary raw materials. The revenue composition is as follows: inorganic salt products 69.91%, veterinary raw materials 18.35%, fluorine-containing chemicals 7.46%, and other products 4.28% [1] Financial Performance - As of June 30, the number of shareholders increased to 14,200, a rise of 58.33% compared to the previous period. The average circulating shares per person decreased by 35.82% to 4,954 shares [2] - For the first half of 2025, the company achieved operating revenue of 499 million yuan, representing a year-on-year growth of 14.20%. The net profit attributable to the parent company was 50.51 million yuan, up 60.66% year-on-year [2] Stock Performance - On September 12, the stock price of Dayang Biological fell by 2.11% to 34.38 yuan per share, with a trading volume of 30.92 million yuan and a turnover rate of 1.28%. The total market capitalization is 2.888 billion yuan [1] - Year-to-date, the stock price has increased by 87.62%, with a decline of 1.72% over the last five trading days, a rise of 6.67% over the last 20 days, and an increase of 23.18% over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent appearance on June 16 [1] Dividend Information - Since its A-share listing, Dayang Biological has distributed a total of 168 million yuan in dividends, with 97.57 million yuan distributed over the past three years [3]

今年以来大洋生物已经1次登上龙虎榜，最近一次登上龙虎榜为6月16日。 资料显示，浙江大洋生物科技集团股份有限公司位于浙江省杭州市建德市大洋镇朝阳路22号，成立日期 1976年1月1日，上市日期2020年10月26日，公司主营业务涉及从事无机盐、兽用原料药等化学原料产品 的生产和销售。主营业务收入构成为：无机盐产品69.91%，兽用原料药18.35%，含氟化学品7.46%，其 他产品4.28%。 9月10日，大洋生物盘中下跌2.02%，截至10:09，报35.42元/股，成交6750.71万元，换手率2.70%，总市 值29.75亿元。 资金流向方面，主力资金净流出334.41万元，特大单买入290.42万元，占比4.30%，卖出507.71万元，占 比7.52%；大单买入1451.10万元，占比21.50%，卖出1568.22万元，占比23.23%。 大洋生物今年以来股价涨93.30%，近5个交易日跌0.76%，近20日涨5.04%，近60日涨25.07%。 责任编辑：小浪快报 大洋生物所属申万行业为：基础化工-化学原料-无机盐。所属概念板块包括：送转填权、化肥、氟化 工、生物农药、增持回购等。 分红方面，大 ...

Group 1 - The average price and sales volume of hydrochloride aminophenol have increased compared to the same period last year [2] - The new production line for hydrochloride aminophenol, with a capacity of 800 tons per year, is still under construction [2] - The specific production timeline and output details will be disclosed by the company in public announcements [2]

Group 1: Potassium Carbonate and Bicarbonate Industry - Potassium carbonate is a key raw material in various industries including chemicals, pharmaceuticals, pesticides, light industry, and food [1] - The company is a leading player in the potassium carbonate and bicarbonate industry, recognized as a national high-tech enterprise and a "little giant" enterprise [1] - The production of potassium bicarbonate is increasingly utilized in food as an acidity regulator and chemical leavening agent, with growing consumption driven by health awareness [1] Group 2: Amprolium Hydrochloride Application - Amprolium hydrochloride is primarily used in poultry, cattle, and sheep, with increasing demand due to rising per capita consumption of poultry meat and the solidification of large-scale farming practices [2] - The company's clean production project for amprolium hydrochloride has been recognized as a "National Torch Program Industrialization Demonstration Project" [2] - The production process incorporates resin adsorption and distillation to address wastewater treatment challenges, showcasing significant environmental advantages [2] Group 3: Fluorochemical Industry Potential - The fluorochemical sector, including fluorinated intermediates, pharmaceuticals, pesticides, dyes, and surfactants, has substantial development potential [3] - The company has over 30 years of experience in fluorochemical production, being a major supplier of 2-chloro-6-fluoro series products in both domestic and international markets [3] - The company possesses pilot technology for PEEK intermediates, which have excellent comprehensive performance [3]

Group 1 - The A-share chemical sector experienced a strong rebound on September 8, with notable stocks such as Jinjing Technology hitting the daily limit up [1] - Dayang Biological surged over 5%, while Jiangshan Co., Lier Chemical, and Yangnong Chemical also saw increases [1]

Company Overview - Zhejiang Dayang Biological Technology Group Co., Ltd. is located in Hangzhou, Zhejiang Province, established on January 1, 1976, and listed on October 26, 2020 [2] - The company primarily engages in the production and sales of chemical raw materials, including inorganic salts and veterinary raw materials [2] - The revenue composition is as follows: Inorganic salt products 69.91%, veterinary raw materials 18.35%, fluorine chemicals 7.46%, and other products 4.28% [2] Stock Performance - As of September 4, the stock price of Dayang Biological fell by 2.21% to 34.90 CNY per share, with a market capitalization of 2.932 billion CNY [1] - Year-to-date, the stock price has increased by 90.46%, with a 5-day increase of 8.59%, a 20-day increase of 10.72%, and a 60-day increase of 41.07% [2] - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent occurrence on June 16 [2] Financial Performance - For the first half of 2025, Dayang Biological achieved a revenue of 499 million CNY, representing a year-on-year growth of 14.20% [2] - The net profit attributable to the parent company was 50.51 million CNY, showing a year-on-year increase of 60.66% [2] - Cumulative cash dividends since the A-share listing amount to 168 million CNY, with 97.57 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, the number of shareholders increased to 14,200, a rise of 58.33% from the previous period [2] - The average number of tradable shares per shareholder decreased by 35.82% to 4,954 shares [2] Market Position - Dayang Biological is classified under the Shenwan industry category of basic chemicals - chemical raw materials - inorganic salts [2] - The company is associated with several concept sectors, including raw materials, synthetic biology, fluorine chemicals, share buybacks, and small-cap stocks [2]

证券代码：003017 股票简称：大洋生物 公告编号：2025-085 浙江大洋生物科技集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 二、本公告日前十二个月公司使用闲置募集资金进行现金管理的情况 截至本公告日，公司及子公司使用闲置募集资金进行现金管理尚未到期的金 额为人民币 11,000.00 万元，未超出公司第六届董事会第五次会议关于使用闲置募 集资金进行现金管理的授权额度。截至本公告日，公司使用闲置募集资金进行现 金管理具体情况如下： | | | | | | | | | | | | | 单位：万元 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 申 | 签 | | | | 产 | | 起 | | 到 | | | 是 | | 序 | 购 | 约 | | | | 品 | 认购金 | | 息 | | 期 | 预期年化 | | | 收 | | | 否 | 投资 | | | | | | | | | | | | ...

证券代码：003017 股票简称：大洋生物 公告编号：2025-085 浙江大洋生物科技集团股份有限公司 关于使用部分闲置募集资金进行现金管理到期赎回的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江大洋生物科技集团股份有限公司（以下简称"公司""本公司"或"大 洋生物"）于 2025 年 8 月 22 日召开第六届董事会第五次会议、第六届监事会第 五次会议，审议通过了《关于继续使用部分闲置募集资金进行现金管理的议案》。 根据《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》 等有关规定，为充分利用公司闲置募集资金，提高资金利用率，在不影响募投项 目建设使用的前提下，公司（含子公司福建舜跃科技股份有限公司，以下简称"福 建舜跃"）使用最高额度不超过 12,000.00 万元（含本数）闲置募集资金进行现金 管理（在此额度内可滚动使用），自董事会审议通过之日起 12 个月之内有效。具 体内容详见公司在《证券时报》《证券日报》和巨潮资讯网（http://www.cninfo.com.cn） 上披露的《关于继续使用部分闲置募集资金进行 ...